Portfolio Lab

Organon & Co.

  • Stock
  • Ticker OGN
  • ISIN US68622V1061
  • NYSE

Health care · Pharmaceuticals · USA

$13.89 −0.14%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Organon & Co. since 05/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

OGNGlobal equities (VT)

$10,000 grew to $4,610. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −82.7% in 03/2026, measured from the peak in 03/2022. The old peak has not been reached again yet.

1-year return
+96.2%
5-year return p.a.
−11.7%
Return p.a. since 05/2021
−11.4%
Volatility p.a.
67.7%
Largest decline
−82.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1,5921,5131,5941,6021,5071,4601,5581,574
Gross profit896841874857741783847869
Net income10987145160-205146108164
Earnings per share0.410.330.560.61-0.780.550.400.60
Balance sheet
Total assets13,10113,15613,50013,55212,86712,99613,17813,401
Liabilities12,62912,61412,76712,64612,11512,09312,17212,208
Equity4725427339067529031,0061,193
Cash6755475996725741,1161,1321,455
Long-term debt8,8608,9368,7818,7838,6288,5538,4798,485
Cash flow
Operating cash flow39075220264141225107370
Capital expenditure-55-32-39-46-45-37-42-44
Free cash flow335431812189618865326

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2024 at +9.9%, weakest 2025 at −50.7%. 1 of 4 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
30 Oct 2026$0.60
31 Jul 2026$0.40
4 May 2026$0.55
24 Feb 2026−$0.78
10 Nov 2025$0.61
6 Aug 2025$0.56
2 May 2025$0.33
28 Feb 2025$0.41
1 Nov 2024$1.38
7 Aug 2024$0.75
3 May 2024$0.78
26 Feb 2024$2.13

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€3.3bn
Market cap in trading currency
$3.65bn
Enterprise value
$10.7bn
P/E
18.0
P/S
0.60
P/B
3.06
EV/Sales
1.76
EV/EBITDA
9.8
Earnings yield
5.5%
FCF yield
18.5%

Results (last four quarters)

Revenue
$6.10bn
Gross profit
$3.24bn
EBITDA
$1.10bn
Net income
$213m
Earnings per share
$0.77
Revenue per share
$23.22
Revenue growth
−1.7%
Earnings growth
+2.5%

Profitability

Gross margin
53.1%
Operating margin
15.6%
Net margin
3.5%
Return on equity
20.3%
Return on assets
1.6%

Balance sheet and cash flow

Cash
$1.46bn
Cash per share
$5.54
Financial debt
$8.55bn
Debt/equity %
717
Current ratio
2.02
Book value per share
$4.54
Operating cash flow
$843m
Free cash flow
$675m

Dividend

Dividend yield
0.72%
Dividend (12 months)
$0.10
Yield (12 months)
0.72%
Payout ratio
13%
Ex-dividend date
9 Nov 2026

Shares and trading

Shares outstanding
263m
Volume
3.57m
Avg. volume 3 months
2.67m
Relative volume
1.3

Price and technicals

Price
$13.89
1 day
−0.1%
52-week high
$13.92
52-week low
$5.70
Distance to 52-week high
−0.2%
Distance to 52-week low
+143.7%
Distance to 50-day line
+0.8%
Distance to 200-day line
+16.8%
RSI (14)
61
Volatility 1M
3.1%

Performance

1 week
−0.1%
1 month
+1.0%
3 months
+1.0%
6 months
+3.4%
YTD
+93.7%
1 year
+86.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has OGN performed since 05/2021?

$10,000 grew to $5,139 by 20 Nov 2026, which is −11.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is OGN?

Volatility was 67.7% per year, measured on monthly returns. The largest decline from a peak was −82.7%, with the low in 03/2026.

How does OGN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +8.4% per year at 15.0% volatility, OGN returned −11.4% at 67.7%. The correlation of monthly returns was 0.35; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Organon & Co. (OGN): Return and risk | Portfolio Lab